A Phase 2 interventional study of Enzalutamide and LY2157299 in Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Active, not recruiting at 4 sites in United States. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 57th largest by enrollment, is one of 9 that started in 2016, is one of 65 in phase 2, reaches primary completion later than 12 of the 37 other live ones, and was the 55th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Hyundai Bioscience Co., Ltd. · Sites in Korea, Republic of
Ages 19+ · Men only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 100 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor of 582 studies on the registry; 71 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 68 (60%) have results posted.
78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 12 open now, 18 under way, none of them phase 3. Of 55 finished, 35 (64%) have results posted.
Among the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, this one is the 16th largest by enrollment of the 72 interventional ones that give a count, is one of 10 that started in 2016, is one of 31 in phase 2, reaches primary completion later than 2 of the 17 other live ones, and was the 31st registered.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins’s Prostatic Neoplasms studies by the year they started, since 2002.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins’s 78 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the progression free survival (PFS) of patients with metastatic castration-resistant prostate cancer treated with enzalutamide in combination with LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Enzalutamide · Drug: LY2157299
Drug: Enzalutamide
160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
Also known as: XTANDI
150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
Also known as: TGF-β receptor inhibitor
Progression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria.
Time frame: 8 years
Number of Participants With (PSA50) Response
PSA50 response in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299
Time frame: 4 years
Overall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2).
Time frame: 8 years
Number of Patients Experiencing Treatment-related Toxicities
Time frame: 8 years
| Milestone | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone |
|---|---|---|
| Started | 37 | 23 |
| Completed | 37 | 23 |
| Not completed | 0 | 0 |
| months | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone |
|---|---|---|
| Progression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria. | 5.6 (2.8 to 8.3) | 7.3 (3.0 to 13.8) |
PSA50 response in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299
| Participants | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone |
|---|---|---|
| Number of Participants With (PSA50) Response | 7 | 6 |
| months | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone |
|---|---|---|
| Overall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2). | 21.6 (16.3 to 36.1) | 24 (20.9 to 36.7) |
| Participants | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone |
|---|---|---|
| Number of Patients Experiencing Treatment-related Toxicities | 23 | 18 |
Collected over Baseline to End of Treatment approximately 8 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: Enzalutamide With LY2157299 | 37/37 (100%) | 5/37 (13.5%) | 20/37 (54.1%) |
| Arm 2: Enzalutamide Alone | 20/23 (87%) | 8/23 (34.8%) | 11/23 (47.8%) |
| Event | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone |
|---|---|---|
| Acute Kidney InjuryRenal and urinary disorders | 0/37 | 2/23 |
| Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders | 0/37 | 2/23 |
| White Blood Cell DecreasedInvestigations | 0/37 | 1/23 |
| SepsisInfections and infestations | 0/37 | 1/23 |
| Treatment Related Secondary MalignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/37 | 1/23 |
| FallInjury, poisoning and procedural complications | 0/37 | 1/23 |
| Abdominal PainGastrointestinal disorders | 1/37 | 0/23 |
| FractureInjury, poisoning and procedural complications | 1/37 | 0/23 |
| HypercalcemiaMetabolism and nutrition disorders | 1/37 | 0/23 |
| FatigueGeneral disorders | 1/37 | 0/23 |
| Event | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone |
|---|---|---|
| FatigueGeneral disorders | 20/37 | 11/23 |
| AnorexiaMetabolism and nutrition disorders | 10/37 | 3/23 |
| Back PainMusculoskeletal and connective tissue disorders | 7/37 | 6/23 |
| InsomniaPsychiatric disorders | 3/37 | 6/23 |
| NauseaGastrointestinal disorders | 9/37 | 2/23 |
| AnemiaBlood and lymphatic system disorders | 7/37 | 2/23 |
| Generalized Muscle WeaknessMusculoskeletal and connective tissue disorders | 2/37 | 4/23 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 6/37 | 1/23 |
| Weight LossInvestigations | 5/37 | 1/23 |
| DiarrheaGastrointestinal disorders | 3/37 | 3/23 |
| Age, Categorical(Participants) | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 3 | 18 |
| >=65 years | 22 | 20 | 42 |
| Age, Continuous(Years) | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone | Total |
|---|---|---|---|
| Median | 68 (53 to 85) | 72 (57 to 84) | 69 (53 to 85) |
| Sex: Female, Male(Participants) | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 37 | 23 | 60 |
| Race (NIH/OMB)(Participants) | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 3 | 10 |
| White | 29 | 18 | 47 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Arm 1: Enzalutamide With LY2157299 | Arm 2: Enzalutamide Alone | Total |
|---|---|---|---|
| United States | 37 | 23 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Dec 2025, 115 months.
Results were first posted in Nov 2026, 10 months after primary completion.
Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 115 months is above that.
Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins →